Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3194-3201

  Dumitrescu, T Pene ^a,b   Anic Milic, T ^c,d   Oreskovic, K ^c,d   Padovan, J ^c,d   Brouwer, K L R ^a   Zuo, P ^b   Schmith, V D ^b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Galapagos Research Center Ltd   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; HALF-LIFE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUTROPHILS; PLASMA; YOUNG ADULT;

EID: 84879025651     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02430-12     Document Type: Article

References (55)

1. Piscitelli SC, Danziger LH, Rodvold KA. 1992. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. 11:137-152.
2. Mazzei T, Mini E, Novelli A, Periti P. 1993. Chemistry and mode of action of macrolides. J. Antimicrob. Chemother. 31(Suppl C):1-9. (Pubitemid 23110695)
3. Shinkai M, Henke MO, Rubin BK. 2008. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol. Ther. 117:393-405.
4. Giamarellos-Bourboulis EJ. 2008. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents 31:12-20. (Pubitemid 350236720)
5. Rubin BK, Henke MO. 2004. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125(2 Suppl):70S-78S. (Pubitemid 38200963)
6. Pfizer Inc. 2013. Zithromax package insert. Pfizer Inc, New York, NY.
7. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. 2002. Long term azithromycin in children with cystic fibrosis: a randomised, placebocontrolled crossover trial. Lancet 360:978-984. (Pubitemid 35284109)
8. Hansen CR, Pressler T, Koch C, Hoiby N. 2005. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4:35-40. (Pubitemid 40347775)
9. Kabra SK, Pawaiya R, Lodha R, Kapil A, Kabra M, Vani AS, Agarwal G, Shastri SS. 2010. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. J. Cyst. Fibros. 9:17-23.
10. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S. 2007. Daily versus weekly azithromycin in cystic fibrosis patients. Eur. Respir. J. 30:487-495. (Pubitemid 351182072)
11. Pirzada OM, McGaw J, Taylor CJ, Everard ML. 2003. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J. Cyst. Fibros. 2:69-71. (Pubitemid 36814092)
12. Wilms EB, Touw DJ, Heijerman HG. 2008. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J. Cyst. Fibros. 7:79-84.
13. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:212-216. (Pubitemid 34214405)
14. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR. 2011. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365:689-698.
15. Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM, Martinez FD, Lemanske RF, Jr, Taussig LM, Mauger DT, Morgan WJ, Sorkness CA, Paul IM, Guilbert T, Krawiec M, Covar R, Larsen G. 2008. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J. Allergy Clin. Immunol. 122:1138-1144.
16. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. 2008. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir. Med. 102:1494-1496.
17. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E. 2010. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm. Pharmacol. Ther. 23:200-207.
18. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. 2006. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61:895-902. (Pubitemid 44570311)
19. Fietta AM, Meloni F. 2008. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr. Med. Chem. 15:716-723. (Pubitemid 351516807)
20. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. 2008. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 85:36-41.
21. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, Boner AL. 2007. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc. 28:194-198.
22. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749-1756. (Pubitemid 37430625)
23. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F. 2010. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303:1707-1715.
24. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. 2006. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 174:566-570. (Pubitemid 44330550)
25. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. 2011. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur. Respir. J. 37: 164-172.
26. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA. 2005. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 172:772-775. (Pubitemid 41324235)
27. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW. 2005. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat. Respir. Med. 4:117-122. (Pubitemid 40613959)
28. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, Reynolds PN. 2008. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178:139-148. (Pubitemid 351957772)
29. Hodge S, Reynolds PN. 2012. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 17:802-807.
30. Steinkamp G, Schmitt-Grohe S, Doring G, Staab D, Pfrunder D, Beck G, Schubert R, Zielen S. 2008. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir. Med. 102: 1643-1653.
31. Hahn DL. 1995. Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J. Fam. Pract. 41:345-351.
32. Hahn DL, Plane MB, Mahdi OS, Byrne GI. 2006. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin. Trials 1:e11. doi:10.1371/journal.pctr.0010011.
33. Hahn DL, Grasmick M, Hetzel S, Yale S. 2012. Azithromycin for bronchial asthma in adults: an effectiveness trial. J. Am. Board Fam. Med. 25:442-459.
34. Davies G, Wilson R. 2004. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 59:540-541. (Pubitemid 38797534)
35. Gomez J, Banos V, Simarro E, Lorenzo CM, Ruiz GJ, Latour J, Garcia ME, Canteras M, Valdes M. 2000. Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev. Esp. Quimioter. 13:379-383.(In Spanish.) (Pubitemid 32125753)
36. Gladue RP, Bright GM, Isaacson RE, Newborg MF. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 33:277-282. (Pubitemid 19071957)
37. Amsden GW. 1996. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin. Ther. 18:56-72.
38. Ballow CH, Amsden GW. 1992. Azithromycin: the first azalide antibiotic. Ann. Pharmacother. 26:1253-1261.
39. Gladue RP, Snider ME. 1990. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34:1056-1060. (Pubitemid 20177355)
40. Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA. 1987. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended halflife and excellent tissue distribution. Antimicrob. Agents Chemother. 31: 1948-1954. (Pubitemid 18009567)
41. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl A):73-82. (Pubitemid 20043952)
42. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. 1994. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int. J. Tissue React. 16: 211-220.
43. Wildfeuer A, Laufen H, Zimmermann T. 1996. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob. Agents Chemother. 40:75-79. (Pubitemid 26019681)
44. Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Banevicius MA, Quintiliani R. 1994. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob. Agents Chemother. 38:2449-2451. (Pubitemid 24304245)
45. Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, Ramirez JA, Summersgill JT. 2002. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J. Infect. Dis. 185:1631-1636. (Pubitemid 34587525)
46. Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, Stupin PD, Belamaric D, Parnham MJ, Erakovic H, V. 2012. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br. J. Pharmacol. 165:1348-1360.
47. Polancec DS, Munic K, Banjanac VM, Vrancic M, Cuzic S, Belamaric D, Parnham MJ, Polancec D, Erakovic H, V. 2012. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J. Leukoc. Biol. 91: 229-243.
48. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. 2005. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob. Agents Chemother. 49:5013-5017. (Pubitemid 41778914)
49. Wilms EB, Touw DJ, Heijerman HG. 2006. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther. Drug Monit. 28:219-225. (Pubitemid 44314952)
50. Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A. 2007. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob. Agents Chemother. 51:103-109. (Pubitemid 46047694)
51. Ballow CH, Amsden GW, Highet VS, Forrest A. 1998. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers. Clin. Drug Invest. 15:159-167. (Pubitemid 28101496)
52. Bergstrand M, Karlsson MO. 2009. Handling data below the limit of quantification in mixed effect models. AAPS J. 11:371-380.
53. Savic RM, Karlsson MO. 2009. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 11:558-569.
54. Olsen KM, San PG, Gann LP, Gubbins PO, Halinski DM, Campbell GD, Jr. 1996. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40:2582-2585. (Pubitemid 26367648)
55. Wildfeuer A, Laufen H, Zimmermann T. 1994. Distribution of orally administered azithromycin in various blood compartments. Int. J. Clin. Pharmacol. Ther. 32:356-360. (Pubitemid 24212081)